IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Boosted by APG Asset Management US Inc.

APG Asset Management US Inc. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 10.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,577 shares of the company's stock after buying an additional 5,139 shares during the period. APG Asset Management US Inc. owned 0.06% of IDEXX Laboratories worth $25,048,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Research Global Investors acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $135,910,000. American Century Companies Inc. raised its stake in shares of IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after acquiring an additional 177,226 shares during the period. TD Asset Management Inc lifted its holdings in shares of IDEXX Laboratories by 178.8% in the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company's stock worth $144,317,000 after acquiring an additional 166,751 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $78,001,000. Finally, 1832 Asset Management L.P. increased its holdings in IDEXX Laboratories by 4,193.1% in the 2nd quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock valued at $62,601,000 after purchasing an additional 125,498 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on IDXX. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, July 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a "buy" rating and a $580.00 price target for the company. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a "hold" rating on the stock in a research note on Monday, June 24th. Finally, Piper Sandler lowered their target price on IDEXX Laboratories from $600.00 to $520.00 and set a "neutral" rating for the company in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $582.25.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $11.27 during trading on Thursday, hitting $509.03. 366,576 shares of the stock were exchanged, compared to its average volume of 471,749. The company has a fifty day moving average price of $484.51 and a two-hundred day moving average price of $497.96. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The company has a market cap of $42.04 billion, a PE ratio of 48.54, a P/E/G ratio of 4.32 and a beta of 1.33. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the prior year, the company earned $2.67 earnings per share. The firm's revenue was up 6.4% compared to the same quarter last year. On average, analysts forecast that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.